Reducing men’s health drug costs: exploring the impact of the Mark Cuban Cost Plus Drug Company model on Medicare savings
In 2022, national health expenditures in the United States were estimated to have grown from 2.7% to 4.3% and increased further in 2023, reaching an estimated $5.2 trillion. Medicare alone, in 2021, accounted for 21% of national health care spending, amounting to $689 billion in total Medicare ex...
Saved in:
Main Authors: | Adam Khan, Karim Kari, Eli Oldham, Jacob Duncan, Matthew Rashid, Matt Vassar |
---|---|
Format: | Article |
Language: | English |
Published: |
MRE Press
2024-12-01
|
Series: | Journal of Men's Health |
Subjects: | |
Online Access: | https://oss.jomh.org/files/article/20241230-446/pdf/JOMH2024092701.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ten‐Year Medicare Use and Spending on the 10 Drugs Selected for Negotiation Under the Inflation Reduction Act
by: Mohammed Essa, et al.
Published: (2025-02-01) -
Impacts of National Reimbursement Drug Price Negotiation on drug accessibility, utilization, and cost in China: a systematic review
by: Zheng Zhu, et al.
Published: (2025-02-01) -
Intercostal Nerve Cryoablation During Lobectomy for Postsurgical Pain: A Safe and Cost-Effective Intervention
by: Daniel L. Miller, et al.
Published: (2024-12-01) -
Outpatient chemotherapy drug costs and expensive chemotherapy drug use in 340B and Non-340B hospitals: an observational study
by: Jianhui Hu, et al.
Published: (2025-01-01) -
Impact of the National Drug Price Negotiation policy on the price, usage, and affordability of anticancer medicines in Shandong Province, China
by: Yaqun Sun, et al.
Published: (2025-01-01)